» Articles » PMID: 20012924

Role of Epithelial-to-mesenchymal Transition (EMT) in Drug Sensitivity and Metastasis in Bladder Cancer

Overview
Specialty Oncology
Date 2009 Dec 17
PMID 20012924
Citations 203
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial-to-mesenchymal transition (EMT) is a process that plays essential roles in development and wound healing that is characterized by loss of homotypic adhesion and cell polarity and increased invasion and migration. At the molecular level, EMT is characterized by loss of E-cadherin and increased expression of several transcriptional repressors of E-cadherin expression (Zeb-1, Zeb-2, Twist, Snail, and Slug). Early work established that loss of E-cadherin and increased expression of MMP-9 was associated with a poor clinical outcome in patients with urothelial tumors, suggesting that EMT might also be associated with bladder cancer progression and metastasis. More recently, we have used global gene expression profiling to characterize the molecular heterogeneity in human urothelial cancer cell lines (n = 20) and primary patient tumors, and unsupervised clustering analyses revealed that the cells naturally segregate into two discrete "epithelial" and "mesenchymal" subsets, the latter consisting entirely of muscle-invasive tumors. Importantly, sensitivity to inhibitors of the epidermal growth factor receptor (EGFR) or type-3 fibroblast growth factor receptor (FGFR3) was confined to the "epithelial" subset, and sensitivity to EGFR inhibitors could be reestablished by micro-RNA-mediated molecular reversal of EMT. The results suggest that EMT coordinately regulates drug resistance and muscle invasion/metastasis in urothelial cancer and is a dominant feature of overall cancer biology.

Citing Articles

Epigenetic modifications in bladder cancer: crosstalk between DNA methylation and miRNAs.

Li W, Luo P, Chen Q, Cheng L, Gan L, Zhang F Front Immunol. 2025; 16:1518144.

PMID: 39981244 PMC: 11841399. DOI: 10.3389/fimmu.2025.1518144.


Potential Contribution of Epithelial Growth Factor Receptor to PI3K/AKT Pathway Dysregulation in Canine Soft Tissue Sarcoma.

Nururrozi A, Igase M, Miyanishi K, Sakurai M, Sakai Y, Tanabe M In Vivo. 2024; 39(1):110-119.

PMID: 39740903 PMC: 11705126. DOI: 10.21873/invivo.13808.


TUBB2B regulates epithelial-mesenchymal transition via interaction with Vimentin to promote glioma migration and invasion.

Li J, Zhou Z, Zhang J, Wang M, Luan X, Zhao M Cancer Cell Int. 2024; 24(1):423.

PMID: 39707368 PMC: 11662515. DOI: 10.1186/s12935-024-03618-5.


Mycobacteria Treatment Inhibits Bladder Cancer Cell Migration, Invasion, and Anchorage-Independent Growth.

Bach-Griera M, Hernandez A, Julian E Int J Mol Sci. 2024; 25(23).

PMID: 39684712 PMC: 11641630. DOI: 10.3390/ijms252312997.


Prognostic Value of TGF-β Expression in Bladder Cancer: A Systematic Review and Meta-analysis.

Kianmehr S, Vahabirad M, Seghatoleslam A, Sadeghi E, Kiani R, Ghasemi H Urol Res Pract. 2024; 50(3):148-153.

PMID: 39495544 PMC: 11562745. DOI: 10.5152/tud.2024.24024.


References
1.
Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

2.
Giese A, Loo M, Tran N, Haskett D, Coons S, Berens M . Dichotomy of astrocytoma migration and proliferation. Int J Cancer. 1996; 67(2):275-82. DOI: 10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9. View

3.
Urist M, Di Como C, Lu M, Charytonowicz E, Verbel D, Crum C . Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol. 2002; 161(4):1199-206. PMC: 1867279. DOI: 10.1016/S0002-9440(10)64396-9. View

4.
Miller V, Riely G, Zakowski M, Li A, Patel J, Heelan R . Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008; 26(9):1472-8. DOI: 10.1200/JCO.2007.13.0062. View

5.
Logothetis C, Hossan E, Sella A, Dexeus F, Amato R . Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst. 1991; 83(4):285-8. DOI: 10.1093/jnci/83.4.285. View